日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Developing and evaluating definitions of real-world clinical endpoints for patients with early-stage triple-negative breast cancer using a United States of America secondary database

利用美国二级数据库，制定和评估早期三阴性乳腺癌患者真实世界临床终点的定义

期刊:
影响因子:
doi:10.1016/j.esmorw.2026.100698
Hu, X; Earla, J R; Cruz, G I; Mohammed, H; Privette, T; Hernandez, A; Krishnan, R; Pan, W; Haiderali, A
肿瘤免疫
肿瘤
乳腺癌
发表日期：2026
文献求助 收藏

Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study

新辅助帕博利珠单抗联合化疗/辅助帕博利珠单抗治疗早期三阴性乳腺癌：KEYNOTE-522随机研究的生活质量结果

期刊:Jnci-Journal of the National Cancer Institute
影响因子:7.2
doi:10.1093/jnci/djae129
Dent, Rebecca; Cortés, Javier; Pusztai, Lajos; McArthur, Heather; Kümmel, Sherko; Bergh, Jonas; Denkert, Carsten; Park, Yeon Hee; Hui, Rina; Harbeck, Nadia; Takahashi, Masato; Untch, Michael; Fasching, Peter A; Cardoso, Fatima; Haiderali, Amin; Jia, Liyi; Nguyen, Allison Martin; Pan, Wilbur; O'Shaughnessy, Joyce; Schmid, Peter
肿瘤
肿瘤免疫
乳腺癌
发表日期：2024
文献求助 收藏

A Narrative Review of the Clinical, Humanistic, and Economic Value of Pembrolizumab-Based Immunotherapy for the Treatment of Breast and Gynecologic Cancers

帕博利珠单抗免疫疗法治疗乳腺癌和妇科癌症的临床、人文和经济价值的叙述性综述

期刊:Oncology and Therapy
影响因子:3.2
doi:10.1007/s40487-024-00308-0
Monberg, Matthew J; Keefe, Steve; Karantza, Vassiliki; Tryfonidis, Konstantinos; Toker, Sarper; Mejia, Jaime; Orlowski, Robert; Haiderali, Amin; Prabhu, Vimalanand S; Aktan, Gursel
肿瘤
肿瘤免疫
乳腺癌
Human
免疫/内分泌
发表日期：2024
文献求助 收藏

Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer

帕博利珠单抗联合化疗一线治疗晚期三阴性乳腺癌

期刊:Future Oncology
影响因子:2.6
doi:10.2217/fon-2023-0301
Haiderali, Amin; Huang, Min; Pan, Wilbur; Akers, Katherine G; Maciel, Dylan; Frederickson, Andrew M
肿瘤
肿瘤免疫
乳腺癌
发表日期：2024
文献求助 收藏

Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland

瑞士一项针对高危早期三阴性乳腺癌患者的新辅助帕博利珠单抗联合化疗后序贯辅助帕博利珠单抗治疗的成本效益研究

期刊:Pharmacoeconomics-Open
影响因子:2.1
doi:10.1007/s41669-023-00445-8
Favre-Bulle, Andrea; Huang, Min; Haiderali, Amin; Bhadhuri, Arjun
肿瘤
肿瘤免疫
乳腺癌
发表日期：2024
文献求助 收藏

Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States

美国新辅助帕博利珠单抗联合化疗后序贯辅助单药帕博利珠单抗治疗高危早期三阴性乳腺癌的成本效益分析

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-022-02365-1
Huang, Min; A Fasching, Peter; Haiderali, Amin; Xue, Weiguang; Yang, Chelsey; Pan, Wilbur; Zhou, Zheng-Yi; Hu, Peter; Chaudhuri, Mitashri; Le Bailly De Tilleghem, Celine; Cappoen, Nicolas; O'Shaughnessy, Joyce
肿瘤
肿瘤免疫
乳腺癌
发表日期：2023
文献求助 收藏

Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis

新辅助免疫疗法和化疗方案治疗高危早期三阴性乳腺癌：系统评价和网络荟萃分析

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-023-11293-4
Cortes, Javier; Haiderali, Amin; Huang, Min; Pan, Wilbur; Schmid, Peter; Akers, Katherine G; Park, Julie E; Frederickson, Andrew M; Fasching, Peter A; O'Shaughnessy, Joyce
肿瘤
肿瘤免疫
乳腺癌
免疫/内分泌
发表日期：2023
文献求助 收藏

Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review

三阴性乳腺癌的经济和人文负担：系统性文献综述

期刊:Pharmacoeconomics
影响因子:4.6
doi:10.1007/s40273-021-01121-7
Huang, Min; Haiderali, Amin; Fox, Grace E; Frederickson, Andrew; Cortes, Javier; Fasching, Peter A; O'Shaughnessy, Joyce
Human
肿瘤
肿瘤免疫
乳腺癌
发表日期：2022
文献求助 收藏